Melanoma Immunotherapy
Evaxion A/S is focused on unresectable melanoma and metastatic melanoma, with clinical interest in treatment strategies for advanced disease that cannot be removed surgically.
- Immune checkpoint therapy
- Combination immunotherapy
- Tumor response assessment
The sponsor’s current clinical activity centers on therapies aimed at improving disease control in adults with advanced melanoma.
Cancer Immunotherapy
The company’s research landscape includes oncology approaches that use immunotherapy to support anti-tumor activity, with emphasis on pairing investigational agents with established PD-1 treatment.
- Anti-tumor immune activation
- Checkpoint inhibitor combinations
- Advanced solid tumors
Its funded work reflects a therapeutic interest in enhancing immune-mediated responses in difficult-to-treat cancer settings.
Therapeutic Vaccines
Evaxion A/S also shows interest in therapeutic vaccine development, particularly approaches designed to complement existing immuno-oncology regimens in melanoma.
- Personalized cancer vaccines
- Antigen-specific immune responses
- Combination with pembrolizumab
This area highlights a focus on vaccine-based strategies for patients with advanced skin cancer.
